Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis

OBJECTIVE: We have developed a new antihyperglycemic agent (teglicar) through the selective and reversible inhibition of the liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1). RESEARCH DESIGN AND METHODS: Glucose production was investigated in isolated hepatocytes and during pancreatic cla...

Descripción completa

Detalles Bibliográficos
Autores principales: Conti, Roberto, Mannucci, Edoardo, Pessotto, Pompeo, Tassoni, Emanuela, Carminati, Paolo, Giannessi, Fabio, Arduini, Arduino
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028366/
https://www.ncbi.nlm.nih.gov/pubmed/21270274
http://dx.doi.org/10.2337/db10-0346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028366/
https://www.ncbi.nlm.nih.gov/pubmed/21270274
http://dx.doi.org/10.2337/db10-0346

Ejemplares similares